Literature DB >> 17303660

Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice.

Toshinori Aoyagi1, Jun-ichi Birumachi, Masami Hiroyama, Yoko Fujiwara, Atsushi Sanbe, Junji Yamauchi, Akito Tanoue.   

Abstract

Arginine-vasopressin (AVP) is known to be involved in maintaining glucose homeostasis, and AVP-resistance is observed in poorly controlled non-insulin-dependent diabetes mellitus subjects, resulting in a lowered plasma volume. Recently we reported that V1a vasopressin receptor-deficient (V1aR(-/-)) mice exhibited a decreased circulating blood volume and hypermetabolism of fat accompanied with impaired insulin-signaling. Here we further investigated the roles of the AVP/V1a receptor in regulating glucose homeostasis and plasma volume using V1aR(-/-) mice. The plasma glucose levels at the baseline or during a glucose tolerance test were higher in V1aR(-/-) than wild-type (WT) mice. Moreover, a hyperinsulinemic-euglycemic clamp revealed that the glucose infusion rate was significantly lower in V1aR(-/-) mice than in WT mice and that hepatic glucose production was higher in V1aR(-/-) mice than WT mice. In contrast to the increased hepatic glucose production, the liver glycogen content was decreased in the mutant mice. These results indicated that the mutant mice had impaired glucose tolerance. Furthermore, feeding V1aR(-/-) mice a high-fat diet accompanied by increased calorie intake resulted in significantly overt obesity in comparison with WT mice. In addition, we found that the circulating plasma volume and aldosterone level were decreased in V1aR(-/-) mice, although the plasma AVP level was increased. These results suggested that the effect of AVP on water recruitment was disturbed in V1aR(-/-) mice. Thus, we demonstrated that one of the AVP-resistance conditions resulting from deficiency of the V1a receptor leads to decreased plasma volume as well as impaired glucose homeostasis, which can progress to obesity under conditions of increased calorie intake.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303660     DOI: 10.1210/en.2006-1315

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  31 in total

Review 1.  The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice.

Authors:  Yoko Fujiwara; Akito Tanoue; Gozoh Tsujimoto; Taka-Aki Koshimizu
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

2.  Insulin hypersensitivity in mice lacking the V1b vasopressin receptor.

Authors:  Yoko Fujiwara; Masami Hiroyama; Atsushi Sanbe; Toshinori Aoyagi; Jun-Ichi Birumachi; Junji Yamauchi; Gozoh Tsujimoto; Akito Tanoue
Journal:  J Physiol       Date:  2007-08-02       Impact factor: 5.182

Review 3.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

4.  Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis.

Authors:  Yuichiro Izumi; Kahori Hori; Yushi Nakayama; Miho Kimura; Yukiko Hasuike; Masayoshi Nanami; Yukimasa Kohda; Yoshinaga Otaki; Takahiro Kuragano; Masuo Obinata; Katsumasa Kawahara; Akito Tanoue; Kimio Tomita; Takeshi Nakanishi; Hiroshi Nonoguchi
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

Review 5.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

Review 6.  Vasopressin receptor antagonists.

Authors:  Biff F Palmer
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

7.  Elucidating the mechanisms by which disulfiram protects against obesity and metabolic syndrome.

Authors:  Michel Bernier; Dylan Harney; Yen Chin Koay; Antonio Diaz; Abhishek Singh; Devin Wahl; Tamara Pulpitel; Ahmed Ali; Vince Guiterrez; Sarah J Mitchell; Eun-Young Kim; John Mach; Nathan L Price; Miguel A Aon; David G LeCouteur; Victoria C Cogger; Carlos Fernandez-Hernando; John O'Sullivan; Mark Larance; Ana Maria Cuervo; Rafael de Cabo
Journal:  NPJ Aging Mech Dis       Date:  2020-07-21

8.  Plasma copeptin and the risk of diabetes mellitus.

Authors:  Sofia Enhörning; Thomas J Wang; Peter M Nilsson; Peter Almgren; Bo Hedblad; Göran Berglund; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Eero Lindholm; Leif Groop; Valeria Lyssenko; Marju Orho-Melander; Christopher Newton-Cheh; Olle Melander
Journal:  Circulation       Date:  2010-05-03       Impact factor: 29.690

9.  Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats.

Authors:  Christopher Taveau; Catherine Chollet; Ludovic Waeckel; Dorinne Desposito; Daniel G Bichet; Marie-Françoise Arthus; Christophe Magnan; Erwann Philippe; Valerie Paradis; Fabienne Foufelle; Isabelle Hainault; Sofia Enhorning; Gilberto Velho; Ronan Roussel; Lise Bankir; Olle Melander; Nadine Bouby
Journal:  Diabetologia       Date:  2015-01-27       Impact factor: 10.122

10.  Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice.

Authors:  Jeremy A Sandgren; Guorui Deng; Danny W Linggonegoro; Sabrina M Scroggins; Katherine J Perschbacher; Anand R Nair; Taryn E Nishimura; Shao Yang Zhang; Larry N Agbor; Jing Wu; Henry L Keen; Meghan C Naber; Nicole A Pearson; Kathy A Zimmerman; Robert M Weiss; Noelle C Bowdler; Yuriy M Usachev; Donna A Santillan; Matthew J Potthoff; Gary L Pierce; Katherine N Gibson-Corley; Curt D Sigmund; Mark K Santillan; Justin L Grobe
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.